Reprogramming Caps at ~75% Epigenetic Age Reversal
🤣 That’s why we make sure the reprogramming technologies we develop can’t take cells back in epigenetic age more than ~75%
New GLP‑1 Pill Approved: Orfoglipron Offers Easier Dosing
New GLP-1 pill approved Foundayo (orfoglipron). Not as much weight loss as oral wegovy but no issues with food or more liquid around taking it. Same price. Not April fools joke.
Light Therapy Eases Fatigue in Hashimoto’s Patients
The effect of photobiomodulation therapy on fatigue and behavioural status in patients with Hashimoto’s thyroiditis https://t.co/AJx5dvqHyw
Doctors Will Swap Pills for Gene Therapies and Epigenetics
Longevity 2.0: Your next doctor won't prescribe pills—they'll prescribe gene therapies, epigenetic reprogramming, and personalized longevity protocols. Medicine is shifting from "treat symptoms" to "reverse aging at the cellular level."
Aging Immune System Shapes Allergy and Biologic Response
Immunosenescence and Allergy: Molecular and Cellular Links Between Inflammaging, Neuro-Immune Aging, and Response to Biologic Therapies https://t.co/DMVxerI64T https://t.co/TUPGK6SqUK
Lilly's Obesity Drug Cleared, Heats up Novo Rivalry
Eli Lilly’s obesity pill approved by FDA, setting up fierce competition with Novo Nordisk https://t.co/8TyrKyyNYP
New Transcriptome Browser Streamlines BLAST DB Creation
Another feature adding to my terminal plasmid editor is a transcriptome browser. Helps you quickly build blast databases from a heap of transcripts in a single fasta file. Gonna add HMM/Pfam detection and Pfam search. I really love this current...
Biotech Platforms Valuation: From mRNA to AI Explained
Mackenzie published a detailed quantitative analysis of biotech platforms. Good place to start to understand how platform companies from Moderna with mRNA to Isomorphic with AI reach patients and are valued in markets.
FDA Threatens Unprecedented Ban Lift on Untested Injectables
If FDA does this, which is highly likely succumbing to pressure from RFK Jr, it crosses a new red line and, as far as I know, is unprecedented. Lifting a ban on drugs that are injected into the bloodstream without...
ER Binding Sites in MCF7 Cells Span 1,000–20,000
If I told you the answer to “How many ER binding sites are in MCF7 cells?” is anywhere between 1,000 and 20,000—would you believe me?
Biotech's Confidence Game Masks Uncertainty and Risk
The Confidence Game in Biotech | Ep. 972 https://t.co/RyMgyMVr54 [ 01:12 ] when that trial works [ 01:30 ] manufactured certainty trap [ 02:02 ] linear mental model failure [ 02:33 ] relay race of risk [ 03:31 ] durability risk reality [ 05:29 ] compressing uncertainty...
Metformin Undermines Exercise’s Insulin‑Sensitivity Gains
As a medical school professor, I've recommended metformin to countless patients. But a new double-blind trial just revealed something alarming. Metformin BLUNTED the insulin-sensitizing benefits of exercise in adults at risk for metabolic syndrome. The findings from a 16-week RCT: -> Exercise +...
Advocating Bills to Expand Right‑to‑Try for Severe Illnesses
Today @theA4LI is at the New Hampshire State House supporting HB 1734 and HB 1735, two bills that would license experimental treatment centers and expand Right to Try protections to patients with severe illness, not just terminal conditions. As a longevity...
AI Clarifies Biotech Limits, Guiding Focused Breakthroughs
“AI will not make all biology predictable. What it will do is make clearer predictions — where prediction is possible — and identify where it is not. This distinction matters because it is likely that the next decade of biotechnology...
FDA Grants RMAT Status to Caribou’s Anti‑BCMA CAR‑T Therapy
1/🚨@CaribouBio announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011 - $CRBU allogeneic anti-BCMA CAR-T Cell Therapy for treating relapsed or refractory multiple myeloma (r/r MM) cancer which is being evaluated in the CaMMouflage...
Paragon Launches Korsana Biosciences, Targeting Alzheimer's
Paragon launched its 7th company today -- Korsana Biosciences, merging into the $CYCN public shell. New ticker will be $KRSA. Lead drug candidate is a shuttled anti-amyloid beta antibody for Alzheimer's disease in early studies. https://t.co/RcJ8adMakm
Vertical AI Delivers Results; General AI Still Limited
Eli Lilly bet $2.75B on AI drug discovery. Best AI model in the world: 0.37% on a reasoning benchmark. Both facts are true simultaneously. Vertical AI that knows your domain: already working. General AI that reasons universally: still finding its ceiling. https://t.co/7iTOUGavT3
Terminal Plasmid Editor Blends Beauty with Functionality
Vibing some more on my in-terminal plasmid editor. Drafting a parts bin that's aesthetically pleasing but also functional. TUI's are wonderful. https://t.co/yu8WUSLgwA
Adiponectin: Key Protector Against Age‑Related Decline
Adiponectin and aging: Mechanistic insights, clinical paradox, and therapeutic horizons "Adiponectin has been implicated in aging and the onset of age-related disease.... Adiponectin signaling protects multiple tissues from age-associated decline... Adiponectin signaling agonists as therapeutics in metabolic and age-related disease." https://t.co/9NcjtjlbjR
Wegovy to Reach 1.2 Million Additional NHS Patients
Novo Nordisk $NVO obesity drug Wegovy will be an option for about 1.2 million more patients in England’s National Health Service - Bloomberg
Biotech Edge: XBI Up 0.9% Amid Market Slump
With today's notable strength in biotech, I note that the XBI was actually marginally positive for the month (0.9%) - seems to be the only sector outside energy that was positive for the month. There have been a modest but...
Study's COVID Vaccine Benefits Limited to Early Pandemic
This tweet and accompanying paper are fairly misleading (note: paper is from July ‘24) There are many issues w the study itself that it’s a bit tough to go into here. But most importantly, the paper concludes: “Our findings support the...
Implantable Islet Cells Offer Injection-Free Diabetes Control
Implantable islet cells could control diabetes without insulin injections by Anne Trafton @MIT Learn more: https://t.co/aPCxukXMW1 #MedTech #HealthTech #Tech #TechForGood https://t.co/hXbxvs5HTM
NineDiagnostics Joins SCbio‑MassBio Drive for AI Cancer Detection
Proud to announce that @NineDiagnostics has been selected for Spring 2026 @SCbio × @MassBio Drive — #biomarkers & #diagnostics track 🎉 One of 11 selected companies. We're focused on building AI-enabled tools to redefine earlier cancer detection and treatment decisions....
Spermidine Linked to Heritable Red Blood Cell Longevity Trait
The longevity factor spermidine is part of a highly heritable complex erythrocyte phenotype associated with longevity https://t.co/rHT8XoWHFz
Cysteine Steers T‑cells Toward Proliferation or Tumor Killing
Cysteine directs T cells to either multiply or attack tumors by fueling distinct metabolic pathways, suggesting new strategies to fine-tune immune responses in cancer therapy. immunometabolism
Low Placebo Response Skews Psychedelic Depression Trial Results
I was interviewed about a study of GH001, vaporized 5-MeO-DMT, for treatment-resistant depression. I commented that, while promising and encouraging, the thing that popped out to me was the almost complete lack of placebo response in the placebo group. Even...
Killer Cells Eradicate Superbugs in a Single Day
Forget Antibiotics: These Killer Cells Wipe Out Deadly Superbugs in a Day by @ShellyFan https://t.co/KVAaK61555 https://t.co/cXP8loNRHn
Elaine Chen Showcases Biotech Deals and Mind‑bending Insights
I'd like to draw your attention to my fantastic @statnews colleague @elaineywchen. She led the way our obesity drug coverage, is a host on our podcast, and writes our biotech newsletter most days. Today has two big examples of the...
First Primate Model of Congenital Deafness Created
Genetically modified marmosets lacking the OTOF gene now serve as the first primate model for human congenital deafness, offering a precise platform to advance gene therapies targeting hearing loss. genetherapy
Nature-Inspired Drug Discovery Discussed on The Long Run
Inspired by Mother Nature, Discovering New Drugs. @viswacolluru of @lifeschemistry is the latest guest on The Long Run. Sponsored by @AlphaSenseInc and Dash Bio. https://t.co/F01HMam6Ul
AI Cuts Drug Discovery From Years to Months
I joined Sam Fazeli for the latest episode of Bloomberg Intelligence's Vanguards of Healthcare podcast and talk about our partnership with Eli Lilly and why I believe algorithmic approaches are reshaping the earliest stages of pharmaceutical R&D. The biggest impact...
Regulators Lag as AI Accelerates Drug Discovery
AI in drug discovery is moving faster than any other sector right now. Eli Lilly. Computational pharma. FDA timelines under pressure. The bottleneck isn't the AI. It's whether regulatory frameworks were designed for a world where drug candidates get identified in months.
FDA Peptide Loosening Could Power Enhanced Games’ Public Debut
If the FDA follows through with lifting restrictions on several peptides, it could unlock a massive market opportunity in performance medicine. One of the most interesting candidates IMHO – with all the bias I have as one of the founders -...
Viral Research Reveals Immune Secrets for Vaccine Design
Here is my talk on how studying viral infections can teach us a lot about the immune system, and how we can use those insights to develop vaccines against viruses. "Night science moments" make science so exciting 🌓 @NightScienceIns @ItaiYanai...
FDA Standards Threaten Affordable Academic Gene Therapies
The scientists behind treating Baby KJ say the FDA is imposing standards that could make it too expensive for them — or any academics — to bring such bespoke therapies to approval. https://t.co/OrxMXBVev4
FDA Hurdles Stall Academic Scaling of Custom Gene Editor
Baby KJ scientists hit speed bump in quest to scale custom gene editor. Stringent FDA requirements could prove stumbling block for academics https://t.co/HsaK7lSuh1 via @Jasonmmast
US VCs Embed in Chinese Labs, Courting Scientists Early
U.S. venture capital firms are no longer waiting for Chinese biotech assets to surface before investing in them — they’re moving upstream, embedding themselves inside labs and courting scientists before they publish their research https://t.co/7kOlGh0sbu
Enhanced Games Could Deliver Credible Data for Peptide Legitimacy
Data, data, data... The @enhanced_games are so much more than just another sports event... "The peptide community has a credibility problem and an evidence problem. Millions of people use compounds backed by rodent studies and Reddit threads. The FDA is cracking...
Gut Bacterial Gene Switches Asparagine: Tumor Fuel or Immune Boost
As a medical school professor, this is one of the most paradigm-shifting findings I've seen this year. Weill Cornell researchers discovered that a single bacterial gene in your gut determines whether the amino acid asparagine fuels tumor growth or supercharges your...
Telomir's IND Filing Sparks Speculative Long On
Telomir filed IND for oral Telomir‑1 in TNBC. Data: clean GLP safety; Phase1/2 planned. Risk: pre‑revenue, weak balance sheet, stock -65%. Trade: speculative long on IND clearance. — Viktor Kopylov, PhD, CFA. More insights: t.me/si14Kopylov
Diabetes Drug Empagliflozin Shows Promise for Early Alzheimer’s
As a medical school professor, I've long suspected that Alzheimer's disease is metabolic at its core. Now we have clinical proof. A Wake Forest trial tested empagliflozin -- a common diabetes drug -- in NON-DIABETIC Alzheimer's patients for the first time. The...
Eli Lilly Acquires Centessa for $7.8B in Neuro Push
Lilly buying $CNTA Centessa (hub & spoke R&D co) for $6.3B + $1.5B CVR. Another neuro deal. Big congrats to @Medicxi, Index ventures, General Atlantic https://t.co/jkC9dv6d3I @medicx
Biogen Buys Apellis for $5.6B, Adds SYFOVRE Sales‑linked CVR
1/Another mega M&A deal in the BioTech and Pharma sector with the acquisition of Apellis Pharmaceuticals - $APLS by Biogen $BIIB for $41 per share in cash at closing in a $5.6B deal. In addition, Apellis stockholders will also receive...
Genetic-Level Solutions Needed; Dyno Tackles Untreatable Diseases
Eric Kelsic said: "To address the root cause of a genetic disease, you need to take action at the genetic level." But this isn’t possible today. If you have sickle cell, Huntington's or cystic fibrosis, there's no cure for you just yet. Here's...
GDF15: AI‑derived Senescence Marker Predicts Mortality
Hopefully blood testing companies can measure GDF15 sooner than later... A deep-learning based biomarker of systemic cellular senescence burden to predict mortality and health outcomes https://t.co/lqM7w3aPfJ
Β‑NMN Restores SIRT1, Halting Liver Cell Aging
β-Nicotinamide mononucleotide prevents senescence and lipid accumulation in hepatic stellate cells by restoring SIRT1 function https://t.co/wyVHZ13QNK
Can One Laptop Control Multiple ONT Sequencers?
Anyone out there know if it is possible to simultaneously run multiple ONT sequencers from a single laptop?
Schwann Cell Exosomes Transfer Ribosomes, miRNAs for Nerve Repair
Glia-to-Axon Transfer of Ribosomes and miRNAs: A Novel Paradigm in Neural Repair "Schwann cell-derived exosomes thus represent both a novel mode of glia–neuron communication and a promising avenue for next-generation therapies for nerve regeneration." https://t.co/xU3zmkA5OA https://t.co/kK3FrVuN7T
Predicting Late‑Stage Trial Outcomes Could Speed Drug Development
Accurately predicting success and failure rate of late stage trials for new drugs could legitimately accelerate pharma. The late stages are where most of the time and money go, and are a bottleneck on bringing drugs to market today.